SGLT2 inhibitors are rapidly becoming seen as cardiac drugs in their own right, above and beyond their role in diabetes.
Written by A/Prof John Amerena MBBS, PhD, FRACP, FCSANZ
A/Prof John Amerena trained in Melbourne before spending four years in the United States at the University of Michigan. He is now a Cardiologist at Barwon Health, and currently has appointments in the Medical School, Deakin University and the Department of Epidemiology and Preventive Medicine at Monash University. He is the Director of the Geelong Cardiology Research Unit which is currently involved in many phase II-III clinical trials, as well as Director of Cardiac Services at Geelong Private Hospital. While still involved in hypertension,he has also become involved in research in atherothrombosis.
Listen to expert interviews.
Click to open in a new tab
PodcastsBrowse the latest monographs from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
